MEDTECH RECEIVES FDA CLEARANCE FOR ROSA SPINE

Montpellier, France, January 5, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce that it has received 510K clearance from the United States Food and Drug Administration (FDA) to market the ROSA™ Spine robot in the United States of America.

Obtaining FDA clearance is a major step in Medtech's development strategy and will allow the Company to market the ROSA™ Spine robot in the United States for minimally invasive surgical procedures on the spine. Around 3 million such procedures are performed worldwide each year.

Bertin Nahum, CEO and Founder of Medtech, said: *"We are thrilled to have FDA approval for ROSA™ Spine. Building on the success that ROSA™ Brain has encountered on the American market, this new key regulatory milestone will allow us to strengthen our position in the world's leading market for spine surgery. In addition, the FDA approval again reflects our capacity to respect the commitments we made at the time of our IPO, growing as a company while offering innovative robotic technology*."

ROSA™ Spine received the CE Mark in 2014 and is currently being used in minimally invasive spine surgery. The first commercial procedure in Europe was performed in December 2014 at the Neurosurgery Department of Amiens-Picardy University Hospital to treat a patient with a degenerative spine disorder through a lumbar fusion with a posterior approach.

The ROSA™ platform was previously approved in the U.S. for brain surgery in 2012. There are currently 27 ROSA™ Brain systems installed in American facilities.

Next communication: Figures for the 2015/2016 half-yearly report (ended 31/12/2015) to be published on January 12, 2016, before the stock exchange.

Press Release

About MEDTECH

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 MEDTECH received the "European Company of the Year Award" in the "robotic neurosurgery" category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the "Révélation" prize in the Mediterranean Deloitte Technology Fast 50 Awards.

In 2015 MEDTECH received the "2016 Company of the Year Award" in the "robotic neurosurgery" category from Frost & Sullivan.

CONTACT MEDTECH	INVESTORS	PRESS	
Christophe Sibillin	Corinne Puissant	Alexandra Prisa (EU)	Joanna Zimmerman (US)
Chief Financial Officer	Tel : +33 (0)1 53 67 36 77	Tel. : +33(0)1 53 67 36 90	Tel : +1 646-536-7006
Tel : +33 (0)4 67 10 77 40	cpuissant@actus.fr	aprisa@actus.fr	jzimmerman@theruthgroup.com